The Department for Health and Social Care has asked NICE to conduct an appraisal of Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late-April 2021 when we will write to you about how you can get involved.
These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.